Abstract
Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) demonstrated that the purified, stable ethyl ester of eicosapentaenoic acid, icosapent ethyl (IPE), added to statins reduced CVD events by 25% (p < 0.001), leading to an expanded indication in the USA. IPE is now approved as an adjunct to maximally tolerated statins to reduce CVD event risk in adults with triglyceride (TG) levels ≥150 mg/dl and either established CVD or diabetes mellitus plus ≥2 additional CVD risk factors. The new indication allows co-administration of IPE for elevated TG levels with statin treatment, enabling effective residual risk reduction in a broader at-risk population beyond what can be achieved with intensive low-density lipoprotein cholesterol control alone.
Original language | English (US) |
---|---|
Pages (from-to) | 155-174 |
Number of pages | 20 |
Journal | Future Cardiology |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
Keywords
- cardiovascular disease
- eicosapentaenoic acid
- heart diseases
- hypertriglyceridemia
- icosapent ethyl
- triglycerides
ASJC Scopus subject areas
- Molecular Medicine
- Cardiology and Cardiovascular Medicine